Serial Changes of Circulating Hepatocyte Growth Factor in Patients Undergoing Open Heart Surgery
Date Issued
2009
Date
2009
Author(s)
Hsu, Wan-Tseng
Abstract
Background— Cardiac allograft vasculopathy (CAV) is the leading cause of death after the first year in heart transplant recipients. An inverse correlation has been reported between circulating hepatocyte growth factor (HGF) levels and the severity of CAV. Before further application, the dynamically regulated production of HGF triggered by surgical insults after open heart surgery should be clarified. ethods and Results— We investigated the serial change in plasma HGF levels in 50 patients undergoing open heart surgery. The patients were divided into two groups, depending on the use of cardiopulmonary bypass (CPB): CPB group and off-pump coronary artery bypass (OPCAB) group. For the initial 34 patients, the measurement time points were 7 (POD7), 30 (POD30), and 90 days postoperatively (POD90). The plasma HGF levels significantly increased from baseline (1296.1 ± 118.9 pg/mL) to 1820.2 ± 104.9 pg/mL (p < 0.05) on POD7, returning to baseline on POD30, and did not have any significant difference between groups at each time point. For the latter 16 patients, the measurement time points were 1(POD1), 5 (POD5), and 7 days postoperatively (POD7) in the postoperative acute phase. The response changes of plasma HGF levels were significantly higher in patients operated upon procedures requiring CPB. onclusions— High plasma HGF levels after open heart surgery may indicate the occurrence or necessity for tissue protection and regeneration after acute systemic insults with temporal effect fading out on the 30th postoperative day and thereafter. Thus the inverse correlation between circulating HGF levels and the severity of CAV detected by intravascular ultrasound at least 1 year after heart transplantation is not influenced by the duration post-operation. Further study is required to clarify the difference in response changes in plasma HGF levels during postoperative acute phase is made by CPB use or patient’s underlying disease indicated for surgical intervention.
Subjects
hepatocyte growth factor
open heart surgery
cardiopulmonary bypass
File(s)![Thumbnail Image]()
Loading...
Name
ntu-98-R95451004-1.pdf
Size
23.32 KB
Format
Adobe PDF
Checksum
(MD5):42a5d5e23068127b15ce1211400f2785